Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Liver Diseases: early-phase trial registry
13 of 34 indexed Liver Diseases trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #451 of 28,707 conditions by registered trial count.
34 US clinical trials · 13 currently recruiting · #451 of 28,707 conditions by registered trial count
Liver Diseases: 34 US clinical trials tracked, 13 recruiting.
Liver Diseases is the subject of 34 registered US clinical trials on ClinicalTrials.gov, 13 of them currently open to new participants. 2 are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most active sponsor is Duke University, running 3 of these trials.
Enrollment posture brief
Registry condition liver-diseases
OPEN 13 | RECR 38% | LATE 2 | EARLY 5 | RANK #451 | SPON 3
Volume-matched condition peers
Nearest open-share peer: Down Syndrome (38% recruiting · 55 trials)
Liver Diseases lists 13 open slots (38% of 34 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Liver Diseases on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Liver Diseases recruits in line with its size-band peers.
13 of 34 indexed trials (38.2%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Liver Diseases trials is spread across many organizations.
Duke University accounts for 3 of 34 trials (8.8%). 26 distinct sponsors appear on at least one study for this condition label.
-
Typical Liver Diseases enrolment sits around 153 participants.
Median target enrolment is 153 among the 34 trials that report a genuine target (sentinel values excluded). 15 of those (44.1%) plan for fewer than 100 participants.
-
Liver Diseases splits between interventional and observational designs.
20 interventional and 14 observational studies make up this index (58.8% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
34 total, page 1 of 1
Observational Pharmaco-Epidemiology Research & Analysis
Epividian
NCT03813862
DILIN - Prospective Study
Duke University
NCT00345930
Liver Transplantation in Patients With CirrHosis and Severe Acute-on-Chronic Liver Failure: iNdications and outComEs
European Foundation for Study of Chronic Liver Failure
NCT04613921
Genetic Collection Protocol
Arbor Research Collaborative for Health
NCT05272319
MAsS Scan as a Predictor of Morbidity and Mortality in Patients With Liver Disease
University of Chicago
NCT05264051
A Trial of Post-Discharge Transitional Care for Patients With Chronic Liver Disease
Indiana University
NCT05733832
Primary Sclerosing Cholangitis in Children
Arbor Research Collaborative for Health
NCT04181138
Noninvasive Subharmonic Aided Pressure Estimation of Portal Hypertension; Renewal
Thomas Jefferson University
NCT05470205
Veteran-Centered Care for Advanced Liver Disease (Vet-CALD)
VA Office of Research and Development
NCT06068491
Enhancing Alcohol Treatment Engagement in Associated Liver Disease (ALD) Patients
Henry Ford Health System
NCT06269510
Effect of Endoscopic Sleeve Gastroplasty in Patients With Obesity and MASH: A Randomized Controlled Trial
Pichamol Jirapinyo, MD, MPH
NCT06138821
Safety and Efficacy of Endoscopic Ultrasound-Guided Portal Pressure Gradient Measurement
Methodist Health System
NCT06336850
The Microbiota Augmentation to Reestablish Commensal Organisms (MARCO) Trial
University of Chicago
NCT06871111
Extracellular RNA Markers of Liver Disease and Cancer
Mayo Clinic
NCT02908048
Social & Contextual Impact on Children Undergoing Liver Transplantation
University of California, San Francisco
NCT04551742
Coronavirus Disease 2019 (Covid-19) Impact on Alcohol-related Liver Disease Patient Outcomes, Care and Alcohol Use
University of California, San Francisco
NCT05191446
Liver Cancer Prevention Randomized Control Trial
M.D. Anderson Cancer Center
NCT05196867
Implementation of a Digital Clinic for Alcohol-associated Liver Disease and Alcohol Use Disorder (DALC)
Mayo Clinic
NCT06319222
RESTORE Declined Livers Study
Washington University School of Medicine
NCT04483102
Monitoring SOF/VEL in Treatment Naïve, HCV Participants With Active Infection
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
NCT03512210
Emricasan, a Caspase Inhibitor, for Evaluation in Subjects With Non-Alcoholic Steatohepatitis (NASH) Fibrosis
Conatus Pharmaceuticals
NCT02686762
Genomic Medicine Risk Assessment Care for Everyone - Implementation Phase
Duke University
NCT06278883
Benign Liver Optimal Core Study (Tissue Acquisition Comparison in Benign Liver Disease)
Parkview Health
NCT03245580
Endoscopic Ultrasound-Guided Portosystemic Pressure Gradient Measurements
Cook Research Incorporated
NCT04668664
Liver Fat and Iron Quantification MRI
University of California, Los Angeles
NCT03162302
Michigan Alcohol Improvement Network- Alcohol Reduction and Treatment Trial
University of Michigan
NCT04473482
Mechanisms of Inflammatory Liver Injury
National Institute of Environmental Health Sciences (NIEHS)
NCT00011284
Breath Analysis Based Disease Biomarkers
Mayo Clinic
NCT04341012
A Study of Dasatinib to See How Liver Impaired and Healthy Subjects Process and React to the Study Drug
Bristol-Myers Squibb
NCT00382668
A Study to Test How Zongertinib is Taken up in the Blood of People With and Without Liver Problems
Boehringer Ingelheim
NCT06692322
A Phase 1, Multicenter, Open-Label Study to Evaluate the Effect of Mild or Moderate Hepatic Impairment on the Multiple-Dose Pharmacokinetics of Ozanimod
Celgene
NCT04639115
Nitazoxanide Pharmacokinetic Parameters in Hepatic Impaired Patients
Genfit
NCT05116826
Feasibility of VIIT in Adults With NASH
Duke University
NCT03861819
Magnetic Resonance Spectroscopy (MRS) Validation Study in Individuals With Nonalcoholic Fatty Liver Disease (NAFLD)
Washington University School of Medicine
NCT00940537
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 4 |
| Phase 2 | 1 |
| Phase 3 | 1 |
| Phase 4 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Liver Diseases records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Liver Diseases trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Liver Diseases page
34 registered trials, 13 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 13 Liver Diseases trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Duke University sponsors the most Liver Diseases trials on record, review their full trial history before evaluating a specific study. See Duke University's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Liver Diseases condition card totals 34 registered trials; most-linked intervention Core Liver Biopsy; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.